Sotatercept (mIgG2a)

• CAT Number: I040096
• Purity: ≥95%

Sotatercept (mIgG2a) (Cat No.: I040096) is a monoclonal antibody fusion protein designed to modulate the transforming growth factor-beta (TGF-β) pathway, particularly by inhibiting activin receptor signaling. It consists of the extracellular domain of activin receptor type IIA fused to a human IgG2a antibody. Sotatercept has shown promise in clinical trials for treating diseases associated with fibrosis and anemia, such as pulmonary arterial hypertension (PAH) and β-thalassemia. By regulating pathways involved in erythropoiesis and fibrosis, sotatercept aims to restore normal cell function and alleviate disease symptoms.

Reference

[1]. Joshi S R, et al. Sotatercept Analog RAP-011 Inhibits Right Ventricular Remodeling and Restores Function in a Mouse Model of Pressure Overload. Circulation. 2020, 142(Suppl_3): A14397-A14397.